Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Business Wire•22/10/2026•08:00 ET
0
Key Highlights
- ➤Stoke will discuss third quarter 2026 business and financial updates October 29
- ➤Zorevunersen is being evaluated in a Phase 3 Dravet syndrome study
- ➤Biogen holds exclusive rest-of-world commercialization rights for zorevunersen
- ➤Stoke retains exclusive zorevunersen rights in the United States, Canada, and Mexico
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Thursday, October 29, 2026, at 4:30 p.m. ET, to discuss third quarter 2026 business and financial updates.
Get started
Create a free account to read the full story.